跳转至内容
Merck
CN
  • A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids.

A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids.

STAR protocols (2021-09-30)
Takuya Okamoto, Yasuko Natsume, Hitomi Yamanaka, Mayuko Fukuda, Ryoji Yao
摘要

Patient-derived organoids (PDOs) recapitulate the cellular heterogeneity of the original colorectal tumor tissue. Here, we describe a protocol to generate genetically modified PDOs to investigate cancer stem cells. This protocol uses the CRISPR-Cas9 system to knock-in the IRES-EGFP-P2A-iCaspase9 cassette into the 3' UTR of the potential cancer stem cell marker gene, which allows us to investigate their potential for self-replication and pluripotency. We describe the procedure for generating mutant PDOs and their application for stem cell research. For complete details on the generation and use of this protocol, please refer to Okamoto et al. Okamoto et al. (2021).

材料
Product Number
品牌
产品描述

Sigma-Aldrich
N-乙酰基-L-半胱氨酸, suitable for cell culture, BioReagent
Sigma-Aldrich
Y-27632 二盐酸盐, ≥98% (HPLC)
Roche
PCR DIG 探针合成试剂盒, sufficient for 25 reaction (50 μL final reaction volume)
Sigma-Aldrich
R-Spondin1 expressing 293T Cell Line, The R-Spondin1-Expressing 293T cell line produces RSPO1, a critical protein used to establish 3D organoid cultures from stomach, small intestine, colon, pancreas, and liver sources.
Roche
DIG发光检测试剂盒, sufficient for 50 blots (10 cm x 10 cm each), kit of 1 (5 components), suitable for hybridization